CIK 0000879407
- Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460408024
- Phone
- +1 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-07 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −10,000 | $19.69 | $197K | 455,433 |
| 2025-01-06 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −21,758 | $19.68 | $428K | 283,093 |
| 2025-01-06 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −10,971 | $20.11 | $221K | 272,122 |
| 2025-01-06 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −19,658 | $19.69 | $387K | 544,727 |
| 2025-01-06 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −9,526 | $20.10 | $191K | 535,201 |
| 2025-01-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −17,765 | $19.68 | $350K | 482,835 |
| 2025-01-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −9,402 | $20.10 | $189K | 473,433 |
| 2025-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −11,520 | $19.05 | $219K | 3,764,252 |
| 2024-12-27 | OLUKOTUN ADEOYE Y Director | Sale 10b5-1 | −2,850 | $20.00 | $57K | 36,740 |
| 2024-12-23 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −12,563 | $19.59 | $246K | 3,775,772 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −12,653 | $20.52 | $260K | 3,702,394 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −8,260 | $21.74 | $180K | 3,694,134 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −5,799 | $22.12 | $128K | 3,688,335 |
| 2024-12-17 | Waddill William D. Director | Sale 10b5-1 | −3,747 | $22.04 | $83K | 40,378 |
| 2024-12-17 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −547 | $22.04 | $12K | 124,167 |
| 2024-12-16 | Waddill William D. Director | Sale 10b5-1 | −3,748 | $21.90 | $82K | 44,125 |
| 2024-12-16 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −5,000 | $21.90 | $110K | 124,714 |
| 2024-12-16 | Vakiener Victoria Director | Sale 10b5-1 | −8,994 | $21.91 | $197K | 21,211 |
| 2024-07-02 | Oliver Tracie Chief Commercial Officer | Sale 10b5-1 | −9,394 | $25.28 | $237K | 127,107 |
| 2024-05-02 | Vakiener Victoria Director | Sale 10b5-1 | −1,799 | $23.31 | $42K | 30,205 |
Page 5 of 23 · 444 trades